{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:41:12Z","timestamp":1784929272469,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In more than 90% of chronic viral hepatitis C (HCV) patients treated with direct-acting antiviral agents (DAAs), a sustained viral response (SVR) was observed. Unfortunately, there are subgroups of subjects who display enduring liver fibrosis and are at high risk of developing hepatocellular carcinoma (HCC). Thus, liver fibrosis evaluation during the follow-up of these patients plays a pivotal role. The gold standard to evaluate hepatic fibrosis is liver biopsy, which is an invasive procedure. Imaging techniques and serum biomarkers have been proposed as safer and cheaper procedures.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> In this study, we evaluated the concordance of transient elastography (TE) with ELF score ( enhanced liver fibrosis) in a cohort of patients with HCV before and after direct-acting antiviral (DAAs) treatment. ELF score has been validated in other chronic liver diseases; the evidence is not available in HCV patients treated with DAAs.<\/jats:p><jats:p><jats:bold>Study design:<\/jats:bold> We prospectively recruited all consecutive HCV patient candidates for DAAs therapy at the University of Naples \u201cFederico II\u201d between April 2015 and July 2016. TE and ELF scores were assessed at baseline, at SVR24, and at SVR48.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> One-hundred-nineteen patients were treated with DAAs, and 94.1% of them reached SVR. A total of 55.5% of patients were males with a mean age of 64.7 \u00b1 9.6\u00a0years. TE results revealed that 12 patients (10%) had F1-2 mild\/moderate fibrosis, and 107 (90%) had F3-4 advanced fibrosis. At baseline, SVR24, and SVR48, the concordance between ELF test and TE was poor: 0.11 (<jats:italic>p<\/jats:italic> = 0.086), 0.15 (<jats:italic>p<\/jats:italic> = 0.124), and 0.034 (<jats:italic>p<\/jats:italic> = 0.002), respectively. However, at SVR24 and SVR48, both methods showed a significant amelioration of liver fibrosis compared to baseline (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). In addition, both ELF index and TE were significantly associated with portal hypertension at baseline, but not with varices and ascites.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our findings suggested that ELF test could predict changes in liver fibrosis, independently of TE. In case of TE unavailability, ELF score could represent an appropriate tool. Notably, in the context of the COVID-19 pandemic, ELF testing should be encouraged to reduce unnecessary access to the hospital and prolonged physical contact.<\/jats:p>","DOI":"10.3389\/fphar.2022.891398","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:54:20Z","timestamp":1660712060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents"],"prefix":"10.3389","volume":"13","author":[{"given":"Valentina","family":"Cossiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"La Civita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Pontillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vallefuoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Brusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Montella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Portella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/cid\/ciaa646","article-title":"The enhanced liver fibrosis index predicts hepatic fibrosis superior to FIB4 and APRI in HIV\/HCV infected patients","volume":"73","author":"Abdel-Hameed","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/17474124.2019.1579641","article-title":"Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers","volume":"13","author":"Agbim","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/gut.2008.149708","article-title":"Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C","volume":"57","author":"Arena","year":"2008","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cmi.2016.09.017","article-title":"Role of assessing liver fibrosis in management of chronic hepatitis C virus infection","volume":"22","author":"Carmona","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.23425","article-title":"Pitfalls of liver stiffness measurement: A 5-year prospective study of 13, 369 examinations","volume":"51","author":"Castera","year":"2010","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12072-010-9240-0","article-title":"Non-invasive assessment of liver fibrosis in chronic hepatitis C","volume":"5","author":"Castera","year":"2011","journal-title":"Hepatol. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0159413","DOI":"10.1371\/journal.pone.0159413","article-title":"Liver stiffness decreases rapidly in response to successful hepatitis C treatment and then plateaus","volume":"11","author":"Chekuri","year":"2016","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1373\/jalm.2018.027359","article-title":"Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis","volume":"3","author":"Day","year":"2019","journal-title":"J. Appl. Lab. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0399-8320(08)73994-0","article-title":"Transient elastography (FibroScan)","volume":"32","author":"de Ledinghen","year":"2008","journal-title":"Gastroenterol. Clin. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Association for the study of the liver. Electronic address and L. European association for the study of the: EASL recommendations on treatment of hepatitis C","volume":"69","author":"European","year":"2018","journal-title":"J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/jgh.14008","article-title":"Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study","volume":"33","author":"Facciorusso","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MCG.0000000000000128","article-title":"Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients","volume":"49","author":"Fernandes","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/MEG.0000000000000392","article-title":"Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease","volume":"27","author":"Fernandez","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/gut.2006.111302","article-title":"Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease","volume":"56","author":"Fraquelli","year":"2007","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/QAI.0000000000000969","article-title":"Isolated hepatitis B core antibody status is not associated with accelerated liver disease progression in HIV\/hepatitis C coinfection","volume":"72","author":"French","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00261-017-1211-7","article-title":"Evaluation of hepatic fibrosis: A review from the society of abdominal radiology disease focus panel","volume":"42","author":"Horowitz","year":"2017","journal-title":"Abdom. Radiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.epidem.2021.100442","article-title":"Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression","volume":"34","author":"Kondili","year":"2021","journal-title":"Epidemics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/a-1713-4372","article-title":"Diagnostic challenges in patients with alcohol-related liver disease","volume":"60","author":"Krag","year":"2022","journal-title":"Z. Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The enhanced liver fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1086\/321819","article-title":"Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection","volume":"33","author":"Monga","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1872-034X.2009.00500.x","article-title":"Liver stiffness measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C","volume":"39","author":"Nitta","year":"2009","journal-title":"Hepatol. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10238-017-0463-4","article-title":"Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naive chronic HCV patients","volume":"18","author":"Omran","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2893.2009.01263.x","article-title":"Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C","volume":"18","author":"Parkes","year":"2011","journal-title":"J. Viral Hepat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/gut.2009.203166","article-title":"Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease","volume":"59","author":"Parkes","year":"2010","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0004563219879962","article-title":"A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease","volume":"57","author":"Patel","year":"2020","journal-title":"Ann. Clin. Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/QAD.0000000000000975","article-title":"Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV\/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV","volume":"30","author":"Peters","year":"2016","journal-title":"AIDS"},{"key":"B31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13453","article-title":"Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents","volume":"72","author":"Putra","year":"2018","journal-title":"Histopathology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"For the study of liver: Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jceh.2018.06.009","article-title":"Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography","volume":"9","author":"Rout","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12664-014-0491-x","article-title":"Usefulness of transient elastography by FibroScan for the evaluation of liver fibrosis","volume":"33","author":"Sharma","year":"2014","journal-title":"Indian J. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"16820","DOI":"10.3748\/wjg.v20.i45.16820","article-title":"Non-invasive diagnosis of advanced fibrosis and cirrhosis","volume":"20","author":"Sharma","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/cid\/ciy807","article-title":"Improvement in hepatic fibrosis biomarkers associated with chemokine receptor inactivation through mutation or therapeutic blockade","volume":"68","author":"Sherman","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3748\/wjg.v22.i4.1711","article-title":"Non-invasive assessment of liver fibrosis: Between prediction\/prevention of outcomes and cost-effectiveness","volume":"22","author":"Stasi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/infdis\/jiv567","article-title":"Association of HIV, hepatitis C virus, and liver fibrosis severity with the enhanced liver fibrosis score","volume":"213","author":"Swanson","year":"2016","journal-title":"J. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","article-title":"Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease","volume":"154","author":"Thiele","year":"2018","journal-title":"Gastroenterology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/jvh.12161","article-title":"Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic Hepatitis B infection","volume":"21","author":"Trembling","year":"2014","journal-title":"J. Viral Hepat."},{"key":"B43","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12876-020-01459-w","article-title":"Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection","volume":"20","author":"Ueda","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cgh.2008.12.015","article-title":"Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease","volume":"7","author":"Vuppalanchi","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e51906","DOI":"10.1371\/journal.pone.0051906","article-title":"Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography","volume":"7","author":"Wahl","year":"2012","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jgh.14103","article-title":"Non-invasive assessments for liver fibrosis: The crystal ball we long for","volume":"33","author":"Wong","year":"2018","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.891398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:54:23Z","timestamp":1660712063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.891398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":46,"alternative-id":["10.3389\/fphar.2022.891398"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.891398","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"891398"}}